{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:34:30Z","timestamp":1790573670179,"version":"4.1.0"},"reference-count":36,"publisher":"American Association for Cancer Research (AACR)","issue":"3","funder":[{"name":"ORIC Pharmaceuticals, Inc.","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>EGFR mutations are common oncogenic drivers in non\u2013small cell lung cancer (NSCLC), and approximately half of patients develop brain metastases over the course of their disease. Patients with nonclassic EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared with patients with classic EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR-mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to address the unmet need for brain-penetrant therapies in NSCLC with EGFR exon 20 insertions or other atypical mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Preclinical and initial phase I clinical data demonstrate the potency, kinome selectivity, efficacy, and brain penetration of enozertinib in NSCLC with EGFR exon 20 insertions and atypical mutations, warranting further clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-3502","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T14:02:03Z","timestamp":1762437723000},"page":"759-772","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non\u2013Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-1192","authenticated-orcid":false,"given":"Melissa R.","family":"Junttila","sequence":"first","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6552-3318","authenticated-orcid":false,"given":"Claire E.","family":"Repellin","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4744-5317","authenticated-orcid":false,"given":"Sumeet","family":"Salaniwal","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2738-3121","authenticated-orcid":false,"given":"Robert","family":"Warne","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-1269","authenticated-orcid":false,"given":"Younho","family":"Lee","sequence":"additional","affiliation":[{"name":"2Voronoi, Inc., Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-7129","authenticated-orcid":false,"given":"Haelee","family":"Kim","sequence":"additional","affiliation":[{"name":"2Voronoi, Inc., Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4838-8992","authenticated-orcid":false,"given":"Kyung Ah","family":"Seo","sequence":"additional","affiliation":[{"name":"2Voronoi, Inc., Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2293-1634","authenticated-orcid":false,"given":"Youngyi","family":"Lee","sequence":"additional","affiliation":[{"name":"2Voronoi, Inc., Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7969-5885","authenticated-orcid":false,"given":"Hong-ryul","family":"Jung","sequence":"additional","affiliation":[{"name":"2Voronoi, Inc., Incheon, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6901-8632","authenticated-orcid":false,"given":"Jason","family":"Baik","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-7695","authenticated-orcid":false,"given":"Jae H.","family":"Chang","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6211-7577","authenticated-orcid":false,"given":"Gina","family":"Andreatta","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-0341","authenticated-orcid":false,"given":"Jason E.","family":"Long","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9844-9767","authenticated-orcid":false,"given":"Jessica D.","family":"Sun","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8821-7786","authenticated-orcid":false,"given":"Stephanie W.","family":"Ni","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4811-5099","authenticated-orcid":false,"given":"Liliana","family":"Soroceanu","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-5444","authenticated-orcid":false,"given":"Lidia C.","family":"Sambucetti","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3193-3304","authenticated-orcid":false,"given":"Akash","family":"Das","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8471-6723","authenticated-orcid":false,"given":"Brenda","family":"Chan","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0163-9087","authenticated-orcid":false,"given":"Padmini","family":"Narayanan","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-0856","authenticated-orcid":false,"given":"Ashley S.","family":"Pereira","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-755X","authenticated-orcid":false,"given":"Edna","family":"Chow Maneval","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-3560","authenticated-orcid":false,"given":"Pratik S.","family":"Multani","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5978-2179","authenticated-orcid":false,"given":"Rupal","family":"Patel","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6841-0236","authenticated-orcid":false,"given":"Matt","family":"Panuwat","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4763-9856","authenticated-orcid":false,"given":"Brian R.","family":"Blank","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-0417","authenticated-orcid":false,"given":"Chudi","family":"Ndubaku","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7917-1459","authenticated-orcid":false,"given":"F. Anthony","family":"Romero","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6287-7105","authenticated-orcid":false,"given":"Anneleen","family":"Daemen","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1303-0447","authenticated-orcid":false,"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[{"name":"3Virginia Cancer Specialists, Fairfax, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-9892","authenticated-orcid":false,"given":"Lori S.","family":"Friedman","sequence":"additional","affiliation":[{"name":"1ORIC Pharmaceuticals, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026020203093333900_bib1","article-title":"Cancer [Internet]","year":"2025 [ 2025 ]"},{"key":"2026020203093333900_bib2","article-title":"Key statistics for lung cancer [Internet]","year":"2025 [ 2025  16]"},{"key":"2026020203093333900_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Prim"},{"key":"2026020203093333900_bib4","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am J Cancer Res"},{"key":"2026020203093333900_bib5","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"2026020203093333900_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"key":"2026020203093333900_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"2026020203093333900_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","article-title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study","volume":"145","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"2026020203093333900_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR Exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thorac Oncol"},{"key":"2026020203093333900_bib10","doi-asserted-by":"crossref","first-page":"102105","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026020203093333900_bib11","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.cllc.2019.11.008","article-title":"Clinicopathologic characteristics, treatment outcomes, and acquired resistance patterns of atypical EGFR mutations and HER2 alterations in stage IV non\u2013small-cell lung cancer","volume":"21","author":"Patil","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2026020203093333900_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026020203093333900_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026020203093333900_bib14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026020203093333900_bib15","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.jtho.2022.07.1080","article-title":"EP16.03-019 landscape of EGFR extracellular domain mutations in advanced non small cell lung carcinoma","volume":"17","author":"Solomon","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026020203093333900_bib16","article-title":"FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications [Internet]","year":"2024 [ 2024  1]"},{"key":"2026020203093333900_bib17","article-title":"FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations [Internet]","year":"2021 [2021  15]"},{"key":"2026020203093333900_bib18","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2021.39.15_suppl.9014","article-title":"Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1\/2 study","volume":"39","author":"Ramalingam","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026020203093333900_bib19","article-title":"Withdrawal of approval of new drug application for EXKIVITY (Mobocertinib succinate) capsule","volume-title":"Equivalent to 40 Milligrams Base [Internet]","author":"Takeda Pharmaceuticals U.S.A., Inc.","year":"2024 [2024  15]"},{"key":"2026020203093333900_bib20","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.00152","article-title":"Safety, tolerability, and antitumor activity of zipalertinib among patients with non\u2013small-cell lung cancer harboring epidermal growth factor receptor Exon 20 insertions","volume":"41","author":"Piotrowska","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026020203093333900_bib21","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3349\/ymj.2022.63.9.799","article-title":"Lazertinib: on the way to its throne","volume":"63","author":"Lee","year":"2022","journal-title":"Yonsei M\u00e9d J"},{"key":"2026020203093333900_bib22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"2026020203093333900_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat Med"},{"key":"2026020203093333900_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"2026020203093333900_bib25","article-title":"Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component","author":"Lee","year":"2022","journal-title":"European patent EP3943491"},{"key":"2026020203093333900_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule\u2013kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2026020203093333900_bib27","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J Med Chem"},{"key":"2026020203093333900_bib28","doi-asserted-by":"crossref","first-page":"11629","DOI":"10.1002\/anie.201805187","article-title":"Discovery of a highly potent and broadly effective epidermal growth factor receptor and HER2 Exon 20 insertion mutant inhibitor","volume":"57","author":"Jang","year":"2018","journal-title":"Angew Chem Int Ed"},{"key":"2026020203093333900_bib29","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"2026020203093333900_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026020203093333900_bib31","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.annonc.2025.06.001","article-title":"Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases","volume":"36","author":"Wilcox","year":"2025","journal-title":"Ann Oncol"},{"key":"2026020203093333900_bib32","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"2026020203093333900_bib33","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"key":"2026020203093333900_bib34","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026020203093333900_bib35","doi-asserted-by":"crossref","first-page":"S769","DOI":"10.1016\/j.annonc.2023.09.2366","article-title":"1333P A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations","volume":"34","author":"Hong","year":"2023","journal-title":"Ann Oncol"},{"key":"2026020203093333900_bib36","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ccell.2022.06.006","article-title":"Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity","volume":"40","author":"Elamin","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-3502\/3668762\/can-25-3502.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-3502\/3726469\/can-25-3502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/3\/759\/3728941\/can-25-3502.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/3\/759\/3728941\/can-25-3502.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:09:40Z","timestamp":1770019780000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/3\/759\/771917\/Enozertinib-Is-a-Selective-Brain-Penetrant-EGFR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-3502","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8284923","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.31228803","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228800","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228788","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228776","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228779","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228773","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228794","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228797","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228785","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228791","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.31228782","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}